Venti has developed a handheld device and AI algorithm that identifies respiratory infections and chronic conditions from volatile organic compounds in breath samples. Built in partnership with Concord Hospital and UNSW Medicine, the platform achieves 94% sensitivity for early-stage pneumonia detection. TGA approval pathway underway.